MétaCan
Menu
← Back to cohort

Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.

2018· review· en· W2807062821 on OpenAlexaff
Hadar Goldvaser, Domen Ribnikar, Habeeb Majeed, Alberto Ocaña, Eitan Amir

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineInternal medicineOncologyBreast cancerTriple-negative breast cancerChemotherapyMeta-analysisAdjuvantStage (stratigraphy)Cancer

Abstract

fetched live from OpenAlex

e12501 Background: In general, early stage TNBC has a poor prognosis. Adjuvant chemotherapy is the gold standard therapy and different regimens have shown improved outcome. It is uncertain whether all regimens have similar efficacy and if all patients with TNBC benefit equally from treatment. Methods: We searched PUBMED to identify randomized trials between 2007 and 2017 comparing different adjuvant chemotherapy regimens in breast cancer. Only studies reporting outcomes for patients with TNBC (or hormone receptor negative disease if data on TNBC not reported) were included. The absolute differences between the experimental and the control group for 5-year disease-free survival (DFS) and overall-survival (OS) were extracted. The absolute benefit from treatment was weighted by study sample size and pooled. We then compared differences between various generations of chemotherapy. Meta-regression analysis explored the influence of study-level median follow-up, tumor size, nodal status, median age, menopausal status and generation of chemotherapy on the benefit from adjuvant chemotherapy. Results: Nineteen studies comprising of 22 comparison groups and 11306 patients with TNBC were included in the analysis. Studies comparing chemotherapy regimens of different generations showed the largest difference in 5 year DFS (weighted mean difference 7.4% for 3rd vs. 2nd generation and 5.9% for 2nd vs. 1st generation). Studies comparing chemotherapy regimens from the same generation showed smaller differences in DFS (1.9%, 1.3% and -3.5% for studies comparing 3rd, 2nd and 1st generations, respectively). The weighted differences in 5 year OS were generally lower (0.4% to 5.8%). Meta-regression results are shown in the Table. Conclusions: Later generations of adjuvant chemotherapy result in substantially improved DFS in patients with early stage TNBC with patients with larger tumor size and nodal involvement gaining most benefit irrespective of age and menopausal status. Large differences in 5 year DFS do not translate to similar effects in 5 year OS. Variable DFS β P value Median age -0.144 0.63 Menopausal 0.374 0.21 T2-T4 0.822 0.001 Node positive 0.525 0.04 Follow-up duration -0.024 0.92

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.022
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.053

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.022
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.036
Bibliometrics0.0060.006
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.174
GPT teacher head0.491
Teacher spread0.317 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBreast Cancer Treatment Studies→French-language works237,207→